Related Experiment Video
Updated: May 5, 2026
Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Better Rejection-Free Survival at Three Years in Kidney Transplant Recipients With Model-Informed Precision Dosing of
Claire Villeneuve1,2,3, Antoine Humeau2,3, Caroline Monchaud1,2,3
1Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France.
Abstract:
The clinical impact of individual dose adjustment of mycophenolate mofetil is still debated, due to conflicting results from randomized clinical trials. This retrospective study aimed to compare 3-year rejection-free survival and adverse effects between adult kidney transplant recipients (KTRs) with or without mycophenolate mofetil model-informed precision dosing (MIPD). MIPD is defined here as mycophenolic acid area under the curve (AUC0-12h) estimation using a limited sampling strategy, pharmacokinetic models and Bayesian estimators; dose recommendation to reach AUC0-12h = 45 mg.h/L; using a widely used online expert system. The study, nested in two multicenter prospective cohort studies, focused on patients who received a mycophenolate drug and were followed up for 1-3 years. Mycophenolate mofetil MIPD was prescribed as per local practice, on a regular basis, when deemed necessary, or not at all. The MIPD group included 341 KTRs and the control group 392. At 3 years, rejection-free survival was respectively 91.2% and 80.6% (P < 0.001) and the cumulative incidence of rejection 5.08% vs. 12.7% per patient × year (hazard ratio = 0.49 (0.34, 0.71), P < 0.001), corresponding to a 2.5-fold reduction. Significant association with rejection-free survival was confirmed in patients at low or high risk of rejection (P = 0.017 and 0.013) and in patients on tacrolimus, but not on cyclosporine (P < 0.001 and 0.205). The mycophenolate mofetil MIPD group had significantly more adverse effects, but most occurred before the first AUC0-12h, suggesting some may be the reason why MIPD was ordered.
Insights
Model-informed precision dosing (MIPD) of mycophenolate mofetil significantly improved 3-year rejection-free survival in kidney transplant recipients. While MIPD increased adverse effects, most occurred early, suggesting careful monitoring is key for optimizing outcomes.
Area of Science:
- Nephrology and Immunology
- Pharmacokinetics and Pharmacogenomics
- Transplantation Medicine
Background:
- The clinical utility of individual mycophenolate mofetil dose adjustments remains controversial due to inconsistent clinical trial data.
- Optimizing immunosuppression is crucial for long-term graft survival post-kidney transplantation.
Purpose of the Study:
- To evaluate the impact of mycophenolate mofetil model-informed precision dosing (MIPD) on 3-year rejection-free survival and adverse events in adult kidney transplant recipients (KTRs).
- To compare outcomes between KTRs receiving MIPD versus standard dosing.
Main Methods:
- Retrospective analysis of 733 adult KTRs nested within two multicenter prospective cohort studies.
- MIPD involved estimating mycophenolic acid AUC0-12h using limited sampling, pharmacokinetic models, and Bayesian estimators, targeting an AUC0-12h of 45 mg·h/L.
- Patients were followed for 1-3 years, with MIPD prescribed based on clinical judgment.
Main Results:
- At 3 years, rejection-free survival was significantly higher in the MIPD group (91.2%) compared to the control group (80.6%) (P < 0.001).
- The cumulative incidence of rejection was lower in the MIPD group (5.08% vs. 12.7% per patient-year), representing a 2.5-fold reduction (HR = 0.49; P < 0.001).
- MIPD showed significant association with rejection-free survival in patients at high or low rejection risk and those on tacrolimus, but not cyclosporine.
Conclusions:
- Mycophenolate mofetil MIPD significantly enhances 3-year rejection-free survival in KTRs, particularly when combined with tacrolimus.
- Although the MIPD group experienced more adverse effects, the majority occurred early, suggesting potential benefits outweigh risks with appropriate monitoring.
- MIPD represents a valuable strategy for optimizing immunosuppression and improving long-term outcomes in kidney transplantation.
Related Concept Videos
01:28Kidney Transplant I: Introduction
01:26Kidney Transplant II: Surgical Procedure
01:16Kidney Transplant III: Nursing Management